E
TARO

Ergoteles’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Ergoteles’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,836
Closed -$283K – 2109
2022
Q2 		$283K Buy
+7,836
New +$299K 0.01% 1136

Other funds holding TARO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's TARO Position: Q3 2022 in Review

Ergoteles sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q3 2022, closing a stake of 7,836 shares — an estimated $283K sold.

Ergoteles first reported a position in TARO in Q2 2022 and held it in 1 quarter. The position peaked at $283K in Q2 2022. 71 funds tracked by Wall St. Rank hold TARO as of Q3 2022.

  • Ergoteles reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 7,836 Taro Pharmaceutical Industries Ltd. shares in Q3 2022, an estimated $283K.
  • Ergoteles first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2022 and held it in 1 quarter.
  • Ergoteles's Taro Pharmaceutical Industries Ltd. position peaked at $283K in Q2 2022.
  • 71 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.